Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety ...
Idiopathic Parkinson's Disease
Drug: CVT-301 Low Dose;Drug: CVT-301 High Dose;Other: Placebo
Acorda Therapeutics
NULL
Completed
30 Years
85 Years
All
351
Phase 3
United States;Canada;Czechia;Poland;Spain;Czech Republic